Glucose-6-phosphate dehydrogenase deficiency screening
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glucose-6-phosphate dehydrogenase deficiency screening On the Web |
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency screening |
FDA on Glucose-6-phosphate dehydrogenase deficiency screening |
CDC on Glucose-6-phosphate dehydrogenase deficiency screening |
Glucose-6-phosphate dehydrogenase deficiency screening in the news |
Blogs on Glucose-6-phosphate dehydrogenase deficiency screening |
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
G6PD defeciency screening in neonates is done routinly in some regions with high incidence. [1]
Screening is done before giving oxidant medication to high risk patients.
There is insufficient evidence to recommend routine screening for G6PD deficiency.
References
- ↑ Kaplan M, Hammerman C (February 2009). "The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective". J Perinatol. 29 Suppl 1: S46–52. doi:10.1038/jp.2008.216. PMID 19177059.